Biologics are transforming pediatric atopic dermatitis — and the pipeline keeps growing

The treatment of atopic dermatitis (AD) in children has undergone a dramatic shift since the FDA approved dupilumab for adolescents in 2019. Before biologics, physicians often undertreated severe pediatric AD due to the toxicity and limitations of older systemic therapies like oral steroids and cyclosporine. Today, multiple biologics — tralokinumab, lebrikizumab, and nemolizumab — plus two JAK inhibitors (upadacitinib and abrocitinib) are approved for ages 12 and up, and dupilumab now extends down to infants as young as 6 months.

New AAD guidelines published in April 2026 strongly recommend these therapies for moderate-to-severe pediatric AD, giving physicians more flexibility to tailor treatment. Research also suggests dupilumab may do more than clear skin — it may reduce the risk of developing asthma and environmental allergies, raising questions about the long-term benefit of keeping patients on therapy.

Key Takeaways:

• Dupilumab is the only biologic/JAK inhibitor approved for children under 2; additional pediatric approvals are expected within the next year
• Phase 3 lebrikizumab data showed ~50% of children aged 6 months–17 years achieved clear or almost-clear skin at week 16, vs. 15% on placebo
• Phase 2 nemolizumab data showed 85–90% EASI reductions at 1 year in children aged 2–11
• New technologies in development could allow biologic dosing once or twice yearly

Why it matters: Uncontrolled AD in childhood affects sleep, school performance, and family well-being. Earlier, more effective treatment could not only clear skin but potentially alter the disease's trajectory — and prevent the allergic comorbidities that often follow.